SOLICITATION NOTICE
66 -- Agilent Bioanalyzer - Notice of Intent
- Notice Date
- 2/15/2017
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2017-Q-66371
- Archive Date
- 3/17/2017
- Point of Contact
- Genesika Carter, Phone: 7704882063
- E-Mail Address
-
fkn7@cdc.gov
(fkn7@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice of Intent The Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases intends to award a sole source firm-fixed price equipment purchase contract to Agilent Technologies. This contract will be for 120 days from time of award. The statutory authority for this sole source acquisition is 10 U.S.C. 2304 (c) (1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The Division of Vector-Borne Diseases is tasked with being able to develop next generation sequencing pipeline for Zika virus. Genomic sequencing of Zika virus is needed to confirm presence of Zika virus in human diagnostic samples, thus confirming diagnostic results. This equipment is required to perform quality control checks throughout the process of DNA library preparation to ensure the protocol functioned as expected and the samples are adequate to be run in the Illumina MiSeq platform. The sequencing pipeline cannot proceed without confirmation of quality of DNA library preparation performed by this instrument. The system should meet the following requirements: 1) 2100 Bioanalyzer with laptop system: • Part number G2943CA • 2100 Bioanalyzer with HP/Compaq laptop PC, printer, 2100 expert software vortex mixer, accessories • Installation • -1YR PC Repair Recovery Service 2) 2100 Bioanalyzer electrophoresis: • Part number G2947CA • 2100 Bioanalyzer electrophoresis set to include electrode cartridge, license key for electrophoresis assay and test chip bundle • 1YR SW Update/Phone Assist The equipment requested is a sophisticated instrument for the analysis of DNA fragment libraries to be used in Illumina platform-based next generation sequencing of Zika virus. The laboratory sequences Zika virus partial or complete genomes to support diagnostic testing. The sequencing pipelines run in the laboratory are specifically designed for use with Illumina MiSeq technology and require the preparation of DNA libraries with equipment and reagents specifically compatible with this technology. DNA libraries must pass quality control checks before sequencing and this instrument, 2100 Bioanalyzer, provides this capability. This instrument reads the concentration and size distribution of the DNA libraries at various steps of the library preparation process and before sequencing in Illumina Miseq equipment to ensure sequencing success. Agilent Technologies is the only vendor to sell this equipment, supplies and consumables for this instrument. Similar products from other brand names are not compatible and will not function with the Illumina-based technologies, the DNA library preparation pipelines for Zika virus sequencing used in the laboratory and the reagents available for this pipeline currently available in the laboratory. The Zika virus sequencing pipelines used in the laboratory require data input specific from this instrument. The NAICS code is 334516 with a size standard of 1,000 employees. No solicitation will be posted to FedBizOpps. We will only issue a solicitation to Agilent Technologies. Agilent Technologies is the only source available to provide this equipment that meets mission critical requirements. This notice of intent is not a request for proposal. A determination to compete this procurement based on response to this notice is solely within the discretion of the Contracting Officer. Interested parties who believe they possess the capability to satisfy this requirement should submit a capability statement demonstrating their ability to meet this requirement. All responses must be sent in writing to Ms. Genesika Carter via email to fkn7@cdc.gov using solicitation number 2017-Q-66371 in the subject line, no later than 12:00pm Eastern Time, March 2, 2017. Place of Contract Performance: Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Division of Vector-Borne Diseases 1324 Calle Canada San Juan, PR 00920
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2017-Q-66371/listing.html)
- Place of Performance
- Address: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 1324 Calle Canada, San Juan, Puerto Rico, 00920, United States
- Zip Code: 00920
- Zip Code: 00920
- Record
- SN04404142-W 20170217/170215235042-a6249cd734b333370e9dbb0d2f8038f8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |